Impact ledger

GSK plc (GSK): the developments shaping its investment case

Follow the evidence affecting GSK plc's demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

Research GSK plc · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-09-11 · 2 reports

GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff

Channel: Direct impact on future revenue streams and R&D expenses; market perception of pipeline strength vs. patent cliff risk.

mixed· 1-5y

2026-09-28 · 6 reports

HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830

Channel: Expansion and de-risking of oncology pipeline through partnership, potential for future revenue from successful drug development.

Bullish· 1-5y

2026-09-02 · 2 reports

Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10%

Channel: Increased competitive pressure in the HIV treatment market, potentially impacting market share and pricing power.

mixed· 3-12m

Evidence affecting valuation assumptions

Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

Date	Assumption	Direction	Interpretation
2026-06-25	net_debt	Bearish	Liability-management transactions often reduce gross debt or push maturities out.
2026-06-25	interest_expense	Bearish	Tender/exchange extends maturity profile and typically lowers near-term interest expense.
2026-06-24	share_count	Bullish	Stock component of consideration dilutes existing acquirer holders.
2026-06-24	net_debt	Bullish	Cash component of consideration is typically debt-funded, raising net debt.
2026-06-24	revenue	Bullish	Acquisition adds target revenue to acquirer P&L on close.

Event impact log

11 events mapped to GSK since 2026-09-02. Evidence through 2026-09-28.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-28	HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830	Expansion and de-risking of oncology pipeline through partnership, potential for future revenue from successful drug development.	Bullish	1-5y	0.30
2026-09-28	HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830	Expansion of oncology pipeline, potential for future revenue streams from a novel mechanism of action.	Bullish	3-12m	0.30
2026-09-28	HUTCHMED doses first patient in global Phase Ia trial of KRAS-EGFR conjugate	Indirect benefit from partner's pipeline progress, diversifying future revenue potential.	Bullish	3-12m	0.30
2026-09-28	HUTCHMED and GSK Initiate Global Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830	Strategic partnership validation and pipeline diversification. While early-stage, it represents a potential future revenue stream.	Bullish	1-3m	0.40
2026-09-28	HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate Therapy	Indirect impact on pipeline value and potential future revenue streams from successful drug development. As a partner, GSK benefits from the progress of the asset.	Bullish	1-5y	0.30
2026-09-28	HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate	Indirect R&D pipeline progression, potential for future revenue diversification and strategic portfolio enhancement.	Bullish	3-12m	0.30
2026-09-11	GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff	Direct impact on future revenue streams and R&D expenses; market perception of pipeline strength vs. patent cliff risk.	mixed	1-5y	0.70
2026-09-11	GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff	Direct impact on current revenue growth and future pipeline expectations. The strong H1 2026 specialty growth is positive, but the looming patent cliff creates long-term uncertainty.	mixed	3-12m	0.70
2026-09-09	Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year Guidance	Competitive landscape in vaccine development and pharmaceutical market. Pfizer's strong performance might indicate broader market conditions or competitive pressures in areas like respiratory vaccines.	watch	1-3m	0.30
2026-09-02	Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10%	Increased competitive pressure in the HIV treatment market, potentially impacting market share and pricing power.	mixed	3-12m	0.40
2026-09-02	FDA approves Gilead's Bixlenvo as HIV franchise sales outlook raised to 9-10%	Increased competition in the HIV treatment market, potentially impacting market share or pricing power.	mixed	3-12m	0.30

Continue this research

Build your GSK plc investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

Research GSK plc · $399/mo

This ledger is regenerated from Market Ontology's public event pipeline. View the GSK entity page →

GSK plc (GSK): the developments shaping its investment case

Research GSK plc · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-09-11 · 2 reports

GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff

Channel: Direct impact on future revenue streams and R&D expenses; market perception of pipeline strength vs. patent cliff risk.

mixed· 1-5y

2026-09-28 · 6 reports

HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830

Channel: Expansion and de-risking of oncology pipeline through partnership, potential for future revenue from successful drug development.

Bullish· 1-5y

2026-09-02 · 2 reports

Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10%

Channel: Increased competitive pressure in the HIV treatment market, potentially impacting market share and pricing power.

mixed· 3-12m

Evidence affecting valuation assumptions

Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

Date	Assumption	Direction	Interpretation
2026-06-25	net_debt	Bearish	Liability-management transactions often reduce gross debt or push maturities out.
2026-06-25	interest_expense	Bearish	Tender/exchange extends maturity profile and typically lowers near-term interest expense.
2026-06-24	share_count	Bullish	Stock component of consideration dilutes existing acquirer holders.
2026-06-24	net_debt	Bullish	Cash component of consideration is typically debt-funded, raising net debt.
2026-06-24	revenue	Bullish	Acquisition adds target revenue to acquirer P&L on close.

Event impact log

11 events mapped to GSK since 2026-09-02. Evidence through 2026-09-28.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-28	HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830	Expansion and de-risking of oncology pipeline through partnership, potential for future revenue from successful drug development.	Bullish	1-5y	0.30
2026-09-28	HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830	Expansion of oncology pipeline, potential for future revenue streams from a novel mechanism of action.	Bullish	3-12m	0.30
2026-09-28	HUTCHMED doses first patient in global Phase Ia trial of KRAS-EGFR conjugate	Indirect benefit from partner's pipeline progress, diversifying future revenue potential.	Bullish	3-12m	0.30
2026-09-28	HUTCHMED and GSK Initiate Global Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830	Strategic partnership validation and pipeline diversification. While early-stage, it represents a potential future revenue stream.	Bullish	1-3m	0.40
2026-09-28	HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate Therapy	Indirect impact on pipeline value and potential future revenue streams from successful drug development. As a partner, GSK benefits from the progress of the asset.	Bullish	1-5y	0.30
2026-09-28	HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate	Indirect R&D pipeline progression, potential for future revenue diversification and strategic portfolio enhancement.	Bullish	3-12m	0.30
2026-09-11	GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff	Direct impact on future revenue streams and R&D expenses; market perception of pipeline strength vs. patent cliff risk.	mixed	1-5y	0.70
2026-09-11	GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff	Direct impact on current revenue growth and future pipeline expectations. The strong H1 2026 specialty growth is positive, but the looming patent cliff creates long-term uncertainty.	mixed	3-12m	0.70
2026-09-09	Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year Guidance	Competitive landscape in vaccine development and pharmaceutical market. Pfizer's strong performance might indicate broader market conditions or competitive pressures in areas like respiratory vaccines.	watch	1-3m	0.30
2026-09-02	Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10%	Increased competitive pressure in the HIV treatment market, potentially impacting market share and pricing power.	mixed	3-12m	0.40
2026-09-02	FDA approves Gilead's Bixlenvo as HIV franchise sales outlook raised to 9-10%	Increased competition in the HIV treatment market, potentially impacting market share or pricing power.	mixed	3-12m	0.30